FDA Approves Ublituximab for Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis
In Dec 2022, the FDA approved BRIUMVI™, a chimeric monoclonal antibody (mAb) labelled for the treatment of RMS

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: